Tekmira Up On Positive Ebola-Related Drug Study; Philips Receives FDA 510(k) Clearance For TAVI Print E-mail
By Mary Davila   
Thursday, 21 August 2014 20:15
Below is a look at some of the headlines for companies that made news in the healthcare sector on August 21, 2014.
Tekmira Pharmaceuticals (NASDAQ: TKMR) shares gained more than four percent after it was reported that one of its drugs showed promising results in animal studies directed at treating Ebola virus disease.

A peer-reviewed study published Wednesday found that Tekmira's lipid nanoparticle provided "complete protection" in monkeys against Marburg virus infection, the symptoms of which are indistinguishable from Ebola.

The drug appeared effective even when administered up to three days following exposure to the virus, which is closely related to Ebola, the company said.

Results in the journal Science Translational Medicine, were trumpeted in a company press release at 2 p.m. Wednesday and later reported, including in the print edition of Thursday's New York Times.

Tekmira's similar development drug, called TKM-Ebola, got a boost August 7 when regulators modified a clinical hold on the drug to a modified hold, potentially clearing the way for human trials.  Regulators halted a Phase I study of TKM-Ebola on July 3 over safety concerns.

Tekmira traded recently at $18.51, up 4.4%.


Royal Philips (NYSE: PHG AEX: PHIA)
today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to market its precision planning application for Transcatheter Aortic-Valve Implantation (TAVI) treatments. Through 3D imaging, the Philips TAVI application provides interventionalists with pre-procedural, high-precision positioning to treat aortic stenosis ailments.

The Philips TAVI planning application is available as part of Philips IntelliSpace Portal 6 – the company's advanced visualization and analysis solution that allows clinicians to access and analyze patient imaging and data virtually anywhere, at any time. The application features a comprehensive measurement package to accommodate virtually all types of TAVI devices.

"As our population ages, minimally invasive TAVI procedures are becoming increasingly popular in the United States, since they provide a non-surgical option for those patients who might have once been considered too high-risk for heart surgery," said Gene Saragnese, CEO, Imaging Systems, Philips Healthcare. "Treating cardiac conditions requires intense precision and our TAVI planning application delivers a solution for aortic device placement to help improve patient care."

Through advanced computed tomography imaging, the TAVI planning application provides planes and panel measurements for precisely placing TAVI devices to manage the risk of under- or oversizing of a TAVI device. It renders images into a 3D heart model to allow interventionalists to orient the device and address less-than-optimal patient cases.

The TAVI technology received FDA approval in 2011. A minimally-invasive procedure, TAVI became a major breakthrough option for high-risk patients who were deemed non-surgical candidates. This procedure can reduce mortality by 60 percent as compared to conventional surgeries1.

The Philips TAVI application will be on display at the upcoming ESC Congress 2014 where attendees can experience Philips cardiology solutions first-hand, with a focus on the continuum of care from prevention and diagnosis, to treatment, recovery and wellness, delivering more efficient and effective cardiovascular care in the treatment of:

Coronary Artery Disease (CAD)
Structural Heart Disease (SHD)
Heart Failure (HF)
For news from the show, visit http://www.philips.com/esc and follow the #ESCcongress conversation via @PhilipsHealth.

Also Thursday:

Accuray Incorporated (Nasdaq:ARAY)
announced today financial results for the fourth fiscal quarter and fiscal year ended June 30, 2014.

BioCorRx, Inc. (BICX)
, developer of the Start Fresh Program, will exhibit at the eMoneyShow in San Francisco, CA August 21-23, 2014.

Galena Biopharma, Inc. (Nasdaq:GALE)
, a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., has been appointed as President and Chief Executive Officer, effective immediately.

Herborium® Group, Inc. (OTC Pink: HBRM)
, a Botanical Therapeutics® Company and the provider of unique all  botanical medicinal products  that target dermatological problems such as acne, and other health  and wellness concerns in the areas of sexual performance as well as energy  depletion and stress,  has successfully deployed a responsive design e-commerce infrastructure and joined $300 billion plus mobile market.

iKang Healthcare Group, Inc. (Nasdaq:KANG)
, the largest provider in China's fast growing private preventive healthcare services market in terms of revenue in 2013, announced today it will attend the Deutsche Bank 13th Annual Global Emerging Markets 1-on-1 Conference to be held on September 3rd to 4th in New York.

Innovus Pharmaceuticals, Inc., (OTCQB:INNV)
, announced today the formation of a Clinical Advisory Board made up of top key opinion leaders in the fields of gynecology and sexual health to support the continued growth of its Zestra® product.

Integra LifeSciences Holdings Corporation (Nasdaq:IART)
today announced that it will present at the following conferences next month:  At 10:35AM ET on Tuesday, September 9, 2014, Mr. Peter Arduini, Integra's President and Chief Executive Officer, and Glenn Coleman, Integra's Chief Financial Officer, will present at the Morgan Stanley Global Healthcare Conference in New York City. 

Intuitive Surgical, Inc. (Nasdaq:ISRG)
, the global leader in robot-assisted minimally invasive surgery, today announced the FDA clearance of Firefly Fluorescence Imaging for the da Vinci® Xi™ Surgical System, which provides surgeons with enhanced visualization during minimally invasive surgical procedures.

NanoString Technologies, Inc. (Nasdaq:NSTG)
, a provider of life science translational research and molecular diagnostic products, today announced that Brad Gray, President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences:  The 2014 Baird Healthcare Conference in New York on Thursday, September 4, 2014 at 12:50 pm ET; The 2014 Morgan Stanley Global Healthcare Conference in New York on Wednesday, September 10, 2014 at 1:30 pm ET.

Quadrant 4 System Corporation (OTCQB:QFOR)
signed a new contract with DragonFly HIX ("DragonFly"), a private healthcare exchange and benefits administration provider based in Jacksonville, Florida.

TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, announced that Lonnie Moulder, CEO, Mary Lynne Hedley, Ph.D., President and COO, and Tim Pearson, Executive Vice President and CFO of TESARO, will participate in several upcoming investor conferences during the month of September, including:  Citi's 9th Annual Biotech Day at the Mandarin Oriental Hotel in Boston on Wednesday, September 3, 2014; Baird's 2014 Health Care Conference at The New York Palace Hotel in New York City on Thursday, September 4, 2014 at 1:25 p.m. EDT. A live webcast will be available by visiting the Investors section of the TESARO website at www.tesarobio.com.

Verde Media Group Inc. (OTC:VMGI) announces key strategic manufacturing partners for the launch and mass production of the initial product line from its majority-owned subsidiary, Beautyject Inc.

Willis North America, a unit of Willis Group Holdings plc (NYSE:WSH), the global risk advisor, insurance and reinsurance broker, today announced a strategic partnership with FusionHealth to help firms reduce risks associated with sleep disorders.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus